WONDFO BIOTECH and Merck Launch a Collaborative Pilot Project to Improve the Access to Diagnosis and Treatment of Primary Thyroid Diseases

On February 25, 2022, GUANGZHOU WONDFO BIOTECH CO.,LTD.(hereinafter referred to as "WONDFO BIOTECH") signed a cooperation agreement with Merck, the world's leading technology company. The advantages of the industry, improve the accessibility of thyroid function testing at the grassroots level, and help improve the ability of grassroots thyroid disease diagnosis and treatment.

Thyroid disease is the second largest disease in the endocrine system. According to the latest epidemiological survey data, the prevalence rate of Chinese adults is as high as 50%, but it is difficult to detect because of its hidden symptoms, and the disease awareness rate is only 0.33%. Thyroid disease can affect multiple systems and organs, jeopardizing human health. Early screening of thyroid function plays an important role in the prevention and treatment of thyroid diseases.

The cooperation project will be the first to start pilot work in grass-roots hospitals. Combined with WONDFO BIOTECH's POCT detection equipment and thyroid disease education for doctors, the accessibility of thyroid disease diagnosis and treatment at the grassroots level is improved. This will further alleviate the problem of insufficient resources for thyroid disease detection and diagnosis and treatment in the grass-roots community, and at the same time improve the efficiency, so that thyroid function can be detected near the county without leaving the county, in response to the national policy of sinking chronic disease medical care.